0000000001300820

AUTHOR

Granito A.

showing 3 related works from this author

Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry

2016

Portal vein thrombosis may occur in cirrhosis; nevertheless, its prevalence, and predictors are still elusive. To investigate this issue, the Italian Society of Internal Medicine undertook the “Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry” (PRO-LIVER). This prospective multicenter study includes consecutive cirrhotic patients undergoing Doppler ultrasound examination of the portal area to evaluate the prevalence and incidence of portal vein thrombosis over a 2-year scheduled follow-up. Seven hundred and fifty-three (68 % men; 64 ± 12 years) patients were included in the present analysis. Fifty percent of the cases were cirrhotic outpatients.…

RegistrieLiver CirrhosisMaleCirrhosisHepatocellular carcinoma030204 cardiovascular system & hematologyGastroenterology0302 clinical medicineEsophageal varicesPrevalenceMedicineProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiVenous ThrombosisPortal VeinAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis; Emergency Medicine; Internal MedicineMiddle AgedPortal vein thrombosisVenous thrombosisSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesSplanchnic venous thrombosisItalyLiverEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.symptomSettore SECS-S/01 - StatisticaHumanmedicine.medical_specialtyLiver CirrhosiSocio-culturaleEsophageal varicesAsymptomatic03 medical and health sciencesAnticoagulants Esophageal varices Hepatocellular carcinoma Liver failure Splanchnic venous thrombosisInternal medicineInternal MedicineHumansAgedHepatologyEsophageal varicebusiness.industryAnticoagulantLiver failureAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis;AnticoagulantsSplanchnic venous thrombosimedicine.diseaseSurgeryProspective StudieSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesMultivariate AnalysisUpper gastrointestinal bleedingComplicationbusinessJournal of Hepatology
researchProduct

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

2020

Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). Results A PNI cut-off value of 31.3 was established using the ROC an…

RNA virusesMaleEtiologyCancer TreatmentHepacivirusKaplan-Meier EstimateBiochemistryCohort StudiesWhite Blood CellsMathematical and Statistical TechniquesRetrospective StudieAnimal CellsAdult; Aged; Aged 80 and over; Antineoplastic Agents; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies; Serum Albumin; Sorafenib; Nutrition AssessmentMedicine and Health Sciences80 and overLymphocytesPathology and laboratory medicineAged 80 and overHepatitis C virusLiver DiseasesStatisticsQLiver NeoplasmsRMedical microbiologyMiddle AgedSorafenibPrognosisOncologyItalyLiver NeoplasmPhysical SciencesVirusesMedicineFemalePathogensCellular TypesHumanResearch ArticleAdultHepatitis B virusCarcinoma HepatocellularImmune CellsScienceImmunologyAntineoplastic AgentsGastroenterology and HepatologySerum Albumin ...Research and Analysis MethodsCarcinomasMicrobiologyAlbuminsGastrointestinal TumorsHumansLymphocyte CountStatistical MethodsSerum AlbuminAgedRetrospective StudiesBlood CellsAdult Aged 80 and over Antineoplastic Agents Carcinoma Hepatocellular Cohort Studies Female Humans Italy Kaplan-Meier Estimate Liver Neoplasms Lymphocyte Count Male Middle Aged Prognosis Retrospective Studies Serum Albumin Sorafenib Nutrition AssessmentBiology and life sciencesFlavivirusesCarcinomaViral pathogensOrganismsCancers and NeoplasmsProteinsHepatocellularHepatocellular CarcinomaCell Biologyprognostic nutritional index (PNI) hepatocellular carcinoma (HCC) sorafenib. survival mRECISTHepatitis virusesMicrobial pathogensNutrition AssessmentMultivariate AnalysisCohort StudieMathematics
researchProduct

Supplementary Material for: Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

2021

Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantinib for HCC are still lacking. Moreover, the prognostic factors for HCC treated with cabozantinib have not been investigated. Methods: We evaluated clinical data and outcome of HCC patients who received cabozantinib in the legal context of named patient use in Italy. Results: Ninety-six patients from 15 centres received cabozantinib. All patients had preserved liver function (Child-Pugh A), mostly …

researchProduct